

Patient ID 321	Patient Name HGH, TESTING	Birth Date 1991-05-15	Sex F	Age 33
Order Number X100476096	Client Order Number X100476096	Ordering Physician UNKNOWN, PROVIDER	Report Notes	
Account Information C7028845 DLMP Jacksonville		Collected 15 Sep 2024 10:00		

B Cell Lymphoma, FISH, Tissue

Result Summary

MCF

MYC rearrangement is not detected.
MYC-IGH fusion is not detected.
BCL2 rearrangement is not detected.
BCL6 rearrangement is not detected.

Interpretation

MCF

These FISH tests are used as part of the diagnosis and classification of B-cell lymphoma. BCL2 rearrangement caused by t(14;18) is a hallmark of follicular lymphomas, but also present in about 20% of DLBCL, particularly in germinal center B-cell subtype. Rearrangement of BCL6 at 3q27 occurs in about 30% of DLBCL. MYC rearrangement caused by translocation t(8;14) or its variants t(2;8) and t(8;22) is present in almost all Burkitt lymphomas and about 10% of DLBCL. Rarely, MYC rearrangement is observed along with BCL2 or BCL6 rearrangement, representing a double-hit event. A double-hit lymphoma is usually associated with an aggressive disease course and a poor prognosis. These results shall be correlated with the clinical and pathologic findings for a final interpretation.

References:

Am J Hematol 2018 93:296–305
Am J Clin Pathol 2020, 153:353–359
J Clin Pathol 2021, 74:650–656

This test was ordered in the context of a Mayo Clinic pathology case (#XX-00-0001), and this result should be interpreted within the context of the pathology report.

Result

MCF

Result Nomenclature

nuc ish(5'MYC,3'MYC)x2(5'MYC con 3'MYCx2)
nuc ish(D8Z2,MYC,IGH)x2
nuc ish(5'BCL2,3'BCL2)x2(5'BCL2 con 3'BCL2x2)
nuc ish(5'BCL6,3'BCL6)x2(5'BCL6 con 3'BCL6x2)

Reason for Referral

MCF

r/o double hit lymphoma

Specimen

MCF

Tissue, Paraffin

Source

MCF

Test

Tissue ID

MCF

XX-00-0001

Method

MCF

Formalin-fixed, paraffin-embedded tissue slides were evaluated by a pathologists. Fluorescent in-situ hybridization (FISH) is performed using the tri-color dual fusion DNA probes for MYC-IGH fusion and break-apart probes for BCL2, BCL6 and MYC rearrangement. 100 cells in total are analyzed in the tumor area for each probe by two technologists. The limit of detection is 10% for MYC-IGH fusion probe and 15% for BCL2, BCL6, and MYC break-apart probes based on the validation of this laboratory. Rearrangements involving BCL2, BCL6 or MYC with breakpoints outside the probe coverage will not be detected. Manual.

Disclaimer

MCF

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration.

Released By

MCF

SONIA RODRIGUEZ

Received: 16 Sep 2024 09:05

Reported: 16 Sep 2024 09:14

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCF	Mayo Clinic Jacksonville Clinical Lab	4500 San Pablo Rd, Jacksonville, FL 32224	Jeffrey Dlott MD	10D0269502